Biovica International AB
BIOVIC B
Company Profile
Business description
Biovica International AB is a biotech company. The company develops and commercializes blood-based diagnostic tests with biomarkers that improve the monitoring and evaluation of modern cancer treatments. The company promotes healthcare through collaboration with cancer institutes and pharmaceutical companies. DiviTum is manufactured by the company and sold as a kit consisting of a reaction plate with reagents that have been optimized for ELISA applications.
Contact
Dag Hammarskjolds vag 54B
Uppsala Science Park
Uppsala752 37
SWET: +46 184444830
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 April 2026
Employees
24
Stocks News & Analysis
stocks
Are declining Chinese births a red flag for A2 Milk?
Demographic challenges in A2’s largest market lead to sell-off.
stocks
Is this ASX share a value trap or bargain?
Cost-cutting the priority as underlying asset values falling on deaf ears.
stocks
Goldman Sachs Earnings: Valuations remain stretched
We raise our fair value estimate for Goldman Sachs stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,108.60 | 16.20 | 0.18% |
| CAC 40 | 8,079.17 | 16.59 | 0.21% |
| DAX 40 | 24,559.86 | 143.26 | -0.58% |
| Dow JONES (US) | 48,747.01 | 258.42 | 0.53% |
| FTSE 100 | 10,151.04 | 24.26 | 0.24% |
| HKSE | 26,585.06 | 97.55 | 0.37% |
| NASDAQ | 23,090.65 | 136.33 | 0.59% |
| Nikkei 225 | 52,774.64 | 216.46 | -0.41% |
| NZX 50 Index | 13,417.17 | 156.76 | -1.15% |
| S&P 500 | 6,840.56 | 43.70 | 0.64% |
| S&P/ASX 200 | 8,782.90 | 14.00 | 0.16% |
| SSE Composite Index | 4,116.94 | 3.29 | 0.08% |